Empowering Pharmacists: South African Court Ruling Greenlights Pharmacist-Prescribed ARVs

By HEOR Staff Writer

August 16, 2023

In a landmark decision, the Pretoria High Court has given the South African Pharmacy Council (SAPC) the judicial green light to implement its Pharmacy-Initiated Management of Antiretroviral Treatment (PIMART) initiative. This allows specially trained pharmacists to manage and prescribe medicine to patients with HIV and tuberculosis.

Judge Elmarie van der Schyff dismissed an application by a doctors’ organisation, the IPA Foundation, to set aside the programme, stating the need for wider access to first-line ART and TPT therapy on a community level is a “dire need”.

The PIMART training course was created to qualify pharmacists in safely and effectively assisting in providing ART, upon successful completion.

This ruling is in line with the World Health Organization’s vision to promote widely accessible primary health care and recognizes the critical role pharmacies play in meeting healthcare needs, especially during pandemics like COVID-19.

Professor Francois Venter, former President of the Southern African HIV Clinicians Society and current Director of Ezintsha, an HIV research organisation, has emphasized the crucial role of pharmacies and pharmacists in expanding HIV services worldwide.

Let’s celebrate this win.

Reference url

Recent Posts

Driving Economic Transformation through Brain Health Investment in Africa

By João L. Carapinha

January 9, 2026

The Johannesburg Communiqué from the Africa Task Force on Brain Health declares that investing in brain health is crucial, as it supports Africa’s economic transformation and Agenda 2063 goals while covering dementia, mental health, brain trauma, and substance abuse. This investment aligns with N...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Therapy: A New Hope fo...

By HEOR Staff Writer

January 8, 2026

Wondering how teclistamab daratumumab therapy could change treatment options for relapsed/refractory multiple myeloma? Johnson & Johnson recently filed a Type II variation application with the European Medicines Agency (EMA), which seeks to expand TECVAYLI® (teclistamab) combined with DARZALE...
Novartis Drug Pricing Agreement

By João L. Carapinha

January 7, 2026

Novartis reached a drug pricing agreement with the US government that lowers prices for innovative medicines, while the firm will launch future drugs at comparable prices across high-income countries. Novartis also introduces direct-to-patient platforms for Mayzent, Rydapt, and Tabrecta via Trump...